The North America sepsis diagnostics market is expected to grow from US$ 279.06 million in 2021 to US$ 513.33 million by 2028. It is estimated to record a CAGR of 9.1% from 2021 to 2028.
High Incidence of Sepsis due to Increasing Nosocomial Infections Drives North America Sepsis Diagnostics Market
Sepsis, fundamentally caused by infection, disproportionately impacts individuals with weakened immune systems. This includes patients undergoing chemotherapy, those who have had a splenectomy, and individuals with conditions like AIDS and diabetes. Among various infection types, nosocomial infections are a primary contributor to illness and death among hospitalized patients. The Centers for Disease Control and Prevention (CDC)’s “2020 National and State Healthcare-Associated Infections Progress Report,” published in 2021, highlighted substantial increases in US healthcare-associated infections between 2019 and 2020: central line-associated bloodstream infections rose by approximately 24%, ventilator-associated events by 35%, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by 15%.
Globally, the Global Sepsis Alliance (GSA) reports that around 26 million people develop sepsis annually, with approximately 8 million deaths. Many of these fatalities, often a consequence of diarrheal diseases or lower respiratory infections, are preventable through early diagnosis and appropriate clinical management. As such, the increasing prevalence of bloodstream infections and the high incidence of sepsis are expected to significantly boost the demand for sepsis diagnostic products, thereby fostering the growth of the North America sepsis diagnostics market during the forecast period.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/BMIRE00025664
North America Sepsis Diagnostics Strategic Insights
North America Sepsis Diagnostics Strategic Insights offers a data-driven analysis of the industry, encompassing current trends, key players, and regional particularities. These insights provide actionable advice, enabling readers to differentiate themselves from competitors by pinpointing untapped segments or developing unique value propositions. By leveraging data analytics, these insights assist industry players—including investors, manufacturers, and other stakeholders—in anticipating market shifts. A future-oriented outlook is critical, helping stakeholders foresee market changes and strategically position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and help them achieve their business objectives within the market.
North America Sepsis Diagnostics Market Segmentation
North America Sepsis Diagnostics Market By Product
Instruments
Reagents and Assays
Blood Culture Media
Software
North America Sepsis Diagnostics Market By Technology
Molecular Diagnostics
By Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, Microbiology)
North America Sepsis Diagnostics Market By Method
Automated Diagnostics and Conventional Diagnostics
North America Sepsis Diagnostics Market By Test Type
Point-of-Care Tests and Laboratory Tests
North America Sepsis Diagnostics Market Regions and Countries Covered
North America
US
Canada
Mexico
North America Sepsis Diagnostics Market leaders and key company profiles
Abbott
BD
bioMerieux SA
Danaher (Beckman Coulter)
F. HOFFMANN-LA ROCHE LTD.
Immunexpress Inc.
Luminex Corporation
T2 Biosystems, Inc.
THERMO FISHER SCIENTIFIC INC.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
